ORIC Earnings Date: Nov 12, 2026 (Estimated) — ORIC Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is ORIC's next earnings date?
ORIC Pharmaceuticals, Inc. (ORIC) is expected to report Q3 2026 earnings on Thursday, November 12, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.38.
How did ORIC do in its last earnings report?
In its most recent report on Aug 3, 2026 (Q2 2026), ORIC Pharmaceuticals, Inc. posted EPS of -$0.38 versus the -$0.36 estimate, a miss of 5.6%. Revenue was $0. The stock's 1-day post-earnings move was +27.1%.
How much does ORIC stock move after earnings?
ORIC beat EPS estimates in 2 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.8% (up or down) in the day after earnings.
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-03 | Q2 2026 | -0.36 | -0.38 | -5.56% | $0 | ❌ Miss | +27.08% | +28.49% | +21.60% |
| 2026-05-04 | Q1 2026 | -0.32 | -0.34 | -6.25% | $0 | ❌ Miss | -0.62% | -6.65% | -18.59% |
| 2026-02-23 | Q4 2025 | -0.36 | -0.30 | +16.67% | $0 | ✅ Beat | +14.60% | +18.53% | -5.21% |
| 2025-11-13 | Q3 2025 | -0.40 | -0.33 | +17.50% | $0 | ✅ Beat | +0.49% | -5.82% | -24.28% |
| 2025-08-12 | Q2 2025 | -0.45 | -0.47 | -4.44% | $0 | ❌ Miss | +3.26% | +0.84% | +14.08% |
| 2025-02-18 | Q4 2024 | -0.51 | -0.51 | +0.00% | $0 | ➖ Inline | +1.15% | +2.93% | -4.84% |
| 2024-11-12 | Q3 2024 | -0.47 | -0.49 | -4.26% | $0 | ❌ Miss | +0.10% | -13.35% | -17.84% |
| 2024-08-12 | Q2 2024 | -0.41 | -0.45 | -9.76% | $0 | ❌ Miss | +6.76% | +21.98% | +19.57% |
Showing last 8 quarters.